WTG
GILD icon

West Tower Group’s Gilead Sciences GILD Stock Holding History

West Tower Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,200
Closed -$270K – 53
2025
Q4 		$270K Buy
+2,200
New +$267K 0.61% 57
2023
Q3 		– Sell
-527
Closed -$40.6K – 687
2023
Q2 		$40.6K Buy
+527
New +$42K 0.03% 245

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

West Tower Group's GILD Position: Q1 2026 in Review

West Tower Group sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 2,200 shares — an estimated $270K sold.

West Tower Group first reported a position in GILD in Q2 2023 and held it in 2 quarters. The position peaked at $270K in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • West Tower Group reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • West Tower Group sold 2,200 Gilead Sciences shares in Q1 2026, an estimated $270K.
  • West Tower Group first reported a position in Gilead Sciences in Q2 2023 and held it in 2 quarters.
  • West Tower Group's Gilead Sciences position peaked at $270K in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on West Tower Group's 13F filing for Q1 2026, filed 29 Apr 2026.